Salivary Gland Infection Market Report 2026

The salivary gland infection market size has grown strongly in recent years. It will grow from $4.45 billion in 2025 to $4.81 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing incidence of bacterial and viral salivary infections, improved access to diagnostic imaging, availability of broad-spectrum antibiotics, expansion of hospital-based ENT services, rising clinical awareness of gland disorders.

The salivary gland infection market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for advanced diagnostic accuracy, rising investments in ENT diagnostic tools, expansion of outpatient diagnostic services, growing focus on patient-centric treatment pathways, increasing integration of imaging and laboratory diagnostics. Major trends in the forecast period include increasing use of advanced imaging diagnostics, rising adoption of targeted antibiotic therapies, growing focus on early infection detection, expansion of minimally invasive treatment approaches, enhanced emphasis on comprehensive diagnostic pathways.

The increasing prevalence of oral health issues is expected to drive the growth of the salivary gland infections market in the coming years. Oral health problems include conditions such as tooth decay, gum infections, and other mouth-related disorders. Factors such as poor oral hygiene, unhealthy dietary habits, and limited access to dental care are contributing to the rise in these issues. The increase in oral health problems raises the risk of salivary gland infections by encouraging bacterial growth and causing blockages in the salivary ducts. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that 32.5 million dental treatments were provided in 2022-23, reflecting a 23.2% increase compared with the previous year. Therefore, the rise in oral health issues is supporting the growth of the salivary gland infections market.

The growing demand for minimally invasive surgery is also expected to drive the salivary gland infections market forward. Minimally invasive surgery uses small incisions and advanced instruments to perform procedures with less pain, faster recovery, and smaller scars compared with traditional surgery. The increasing adoption of minimally invasive techniques is driven by their advantages, including reduced pain, quicker healing, fewer complications, and enhanced precision through technologies such as robotics and laparoscopic equipment. These procedures treat salivary gland infections by using small incisions and specialized tools to drain abscesses or remove blockages, reducing recovery time and complications. For instance, in June 2024, the American Society of Plastic Surgeons, a US-based non-profit organization, reported a 7% increase in minimally invasive procedures in 2023 compared with the previous year. Therefore, the rising preference for minimally invasive surgery is driving growth in the salivary gland infections market.

Key companies in the salivary gland infections market are focusing on technological innovations, particularly in minimally invasive procedures, to enhance treatment outcomes, speed up patient recovery, and improve overall healthcare efficiency. Minimally invasive procedures involve smaller incisions and specialized instruments, causing less tissue damage and promoting faster healing. For example, in March 2024, Amrita Hospital, an India-based healthcare institution, launched the Amrita Centre for minimally invasive salivary gland surgery, providing advanced treatments for salivary disorders using endoscopy. This approach reduces the need for traditional surgery while preserving gland function. The launch included a two-day workshop featuring expert demonstrations.

Major companies operating in the salivary gland infection market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co Inc, AbbVie Inc, AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly And Company, FUJIFILM Holdings Corporation, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Astellas Pharma Inc, Sandoz International GmbH, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc, Mylan NV, Zydus Cadila Healthcare Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Cipla Limited, Sanofi SA, Bayer AG, Perrigo Company plc.

North America was the largest region in the salivary gland infection market in 2025. The regions covered in the salivary gland infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the salivary gland infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the salivary gland infection market by increasing costs of imported diagnostic imaging equipment, laboratory reagents, surgical instruments, and pharmaceutical ingredients. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces cost pressures on equipment sourcing. These tariffs are raising diagnostic and treatment costs and influencing procurement decisions. However, they are also encouraging domestic production of medical devices, localized pharmaceutical manufacturing, and investment in regional healthcare infrastructure.

The salivary gland infection market research report is one of a series of new reports that provides salivary gland infection market statistics, including salivary gland infection industry global market size, regional shares, competitors with a salivary gland infection market share, detailed salivary gland infection market segments, market trends and opportunities, and any further data you may need to thrive in the salivary gland infection industry. This salivary gland infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Salivary gland infections are caused by bacterial or viral agents affecting the salivary glands, leading to symptoms such as swelling, pain, and dry mouth. These infections commonly involve major glands like the parotid, submandibular, and sublingual glands and may result from blockages, dehydration, or infections such as mumps.

The main diagnostic methods for salivary gland infections include plain radiography, sialography, computed tomography (CT), magnetic resonance imaging (MRI), radionuclide scintigraphy, high-resolution ultrasonography, and other techniques. Plain radiography uses X-rays to produce images of internal structures, including the salivary glands, and helps detect stones or calcifications. Treatment options include medications, surgery, aspiration, home care, and other therapies. These services are offered in hospitals, clinics, medical research centers, academic institutions, and other end-user settings.

The salivary gland infections market consists of revenues earned by entities by providing services such as ultrasound, rehabilitation therapy, and glandular duct dilation procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The salivary gland infections market includes sales of antibiotics, antiviral drugs, anti-inflammatory medications, and biocompatible stents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.